[144] Beta Bionics, Inc. SEC Filing

Rhea-AI Filing Summary

Insider sale notice for Beta Bionics, Inc. (BBNX): The filer reports a proposed sale of 15,018 common shares with an aggregate market value of $311,836.91 to be executed on 10/01/2025 on NASDAQ. The filing states the shares were acquired on 10/01/2025 through stock options granted by the issuer and paid for in cash.

The filing also discloses four recent transactions by the same seller totaling 20,000 shares sold between 08/19/2025 and 09/08/2025 with combined gross proceeds of $331,831.80. The filer certifies no undisclosed material adverse information and includes broker details for the planned sale.

Positive

• Complete disclosure of proposed sale including broker, exchange, and aggregate market value
• Recent transaction history for the seller is provided, improving transparency
• Seller attests there is no undisclosed material adverse information

Negative

• Significant insider selling activity: 15,018 shares proposed plus 20,000 shares sold recently, which may signal insider liquidity
• Concentration of dispositions by one individual over a short period could be viewed negatively by some investors

Insights

Securities Analyst

TL;DR: Insider plans to sell 15,018 shares (~$312k) after multiple recent disposals totaling 20,000 shares; disclosure is routine but notable for volume.

The filing shows a common procedure under Rule 144: an insider exercised stock options and intends to liquidate 15,018 shares via Merrill Lynch on NASDAQ with an indicated aggregate market value of $311,836.91. Recent sales by the same individual between August and September 2025 totaled 20,000 shares for ~$331,832, suggesting ongoing disposition of holdings. For investors, the transaction is material only as a disclosure of insider liquidity rather than an operational indicator; no earnings or corporate event data are provided.

Corporate Governance Expert

TL;DR: The notice is a standard Rule 144 disclosure; multiple recent insider sales merit attention for governance and insider ownership trends.

The filer affirms the absence of undisclosed material adverse information and records acquisition via stock options on the same date as the planned sale. The concentration of sales by the same individual over a short period may affect perceptions of insider sentiment and dilution, but the filing contains no allegation of misconduct or material issuer changes. Documentation appears complete with broker and sale schedule details.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 6002 El Tordo 2nd FL PO Box 7297 Rancho Santa Fe CA 92067	15018	311836.91	43470125	10/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/01/2025	Stock Options	issuer			15018	10/01/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Stephen Feider 11 HUGHES Irvine CA 92618	Common	09/08/2025	9900	209152.15
Stephen Feider 11 HUGHES Irvine CA 92618	Common	09/05/2025	100	2100
Stephen Feider 11 HUGHES Irvine CA 92618	Common	08/22/2025	4413	75082.65
Stephen Feider 11 HUGHES Irvine CA 92618	Common	08/19/2025	5587	1497

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for Beta Bionics (BBNX) disclose?

The filing discloses a proposed sale of 15,018 common shares valued at $311,836.91, to be sold on 10/01/2025 on NASDAQ through Merrill Lynch.

How were the shares being sold by the filer acquired?

The shares were acquired on 10/01/2025 via stock options from the issuer and paid for in cash according to the filing.

Has the seller recently sold other Beta Bionics shares?

Yes. The filer sold 9,900 shares on 09/08/2025, 100 shares on 09/05/2025, 4,413 shares on 08/22/2025, and 5,587 shares on 08/19/2025.

What were the gross proceeds from recent sales by the seller?

The disclosed gross proceeds from the listed recent sales sum to $331,831.80 across four transactions.

Which broker and exchange are specified for the planned sale?

The broker is listed as Merrill Lynch (Rancho Santa Fe, CA address provided) and the exchange is NASDAQ.